Several ongoing trials—like dual CAR-NK19/70 (NCT05842707, NCT05703854), TROP2-CAR-NK (NCT06066424, NCT05922930), NKG2D CAR-NK for ovarian cancer (NCT05776355), and anti-CD19 CAR-NK for SLE (KN5501)—highlight the significant preclinical and early clinical interest in using CAR-NK cells for both cancer and autoimmune diseases [315]. This evidence concerns the gene CD19 and autoimmune disease.